-
1
-
-
0035822038
-
The hemophilias - from royal genes to gene therapy
-
Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
-
(2001)
N Engl J Med
, vol.344
, pp. 1773-1779
-
-
Mannucci, P.M.1
Tuddenham, E.G.2
-
2
-
-
34247625634
-
Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors
-
Dasgupta S, Navarrete AM, Delignat S et al. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors. Immunol Lett 2007; 110: 23-8.
-
(2007)
Immunol Lett
, vol.110
, pp. 23-28
-
-
Dasgupta, S.1
Navarrete, A.M.2
Delignat, S.3
-
3
-
-
0028268941
-
Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates
-
de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
-
(1994)
Thromb Haemost
, vol.71
, pp. 544-547
-
-
de Biasi, R.1
Rocino, A.2
Papa, M.L.3
Salerno, E.4
Mastrullo, L.5
De Blasi, D.6
-
4
-
-
0026548917
-
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
-
Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
-
(1992)
Lancet
, vol.339
, pp. 594-598
-
-
Ehrenforth, S.1
Kreuz, W.2
Scharrer, I.3
-
5
-
-
0141482007
-
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
-
Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
-
(2003)
Blood
, vol.102
, pp. 2358-2363
-
-
Gringeri, A.1
Mantovani, L.G.2
Scalone, L.3
Mannucci, P.M.4
-
6
-
-
47649092909
-
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A
-
Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112: 240-9.
-
(2008)
Blood
, vol.112
, pp. 240-249
-
-
Lacroix-Desmazes, S.1
Navarrete, A.M.2
Andre, S.3
Bayry, J.4
Kaveri, S.V.5
Dasgupta, S.6
-
7
-
-
70349310353
-
Factor VIII inhibitors: risk factors and methods for prevention and immune modulation
-
Zhang AH, Skupsky J, Scott DW. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 2009; 37: 114-24.
-
(2009)
Clin Rev Allergy Immunol
, vol.37
, pp. 114-124
-
-
Zhang, A.H.1
Skupsky, J.2
Scott, D.W.3
-
8
-
-
34247330151
-
A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels
-
Viel KR, Machiah DK, Warren DM et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109: 3713-24.
-
(2007)
Blood
, vol.109
, pp. 3713-3724
-
-
Viel, K.R.1
Machiah, D.K.2
Warren, D.M.3
-
9
-
-
0031598278
-
Inhibitors occur more frequently in African-American and Latino haemophiliacs
-
Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
-
(1998)
Haemophilia
, vol.4
, pp. 68
-
-
Aledort, L.M.1
Dimichele, D.M.2
-
10
-
-
6644227418
-
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
-
Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
-
(2001)
Haemophilia
, vol.7
, pp. 267-272
-
-
Astermark, J.1
Berntorp, E.2
White, G.C.3
Kroner, B.L.4
-
11
-
-
0028266130
-
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group
-
Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
-
(1994)
Blood
, vol.83
, pp. 2428-2435
-
-
Bray, G.L.1
Gomperts, E.D.2
Courter, S.3
-
12
-
-
0027473752
-
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
-
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
-
(1993)
N Engl J Med
, vol.328
, pp. 453-459
-
-
Lusher, J.M.1
Arkin, S.2
Abildgaard, C.F.3
Schwartz, R.S.4
-
13
-
-
64749096663
-
Inhibitors of factor VIII in black patients with hemophilia
-
Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
-
(2009)
N Engl J Med
, vol.360
, pp. 1618-1627
-
-
Viel, K.R.1
Ameri, A.2
Abshire, T.C.3
-
14
-
-
79959524146
-
A haplotype map of the human genome
-
Altshuler D, Brooks LD, Chakravarti A, Collins FS, Consortium IH. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
-
(2005)
Nature
, vol.437
, pp. 1299-1320
-
-
Altshuler, D.1
Brooks, L.D.2
Chakravarti, A.3
Collins, F.S.4
Consortium, I.H.5
-
15
-
-
35348983887
-
A second generation human haplotype map of over 3.1 million SNPs
-
Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
-
(2007)
Nature
, vol.449
, pp. 851-861
-
-
Frazer, K.A.1
Ballinger, D.G.2
Cox, D.R.3
-
16
-
-
0035094764
-
Variation is the spice of life
-
Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27: 234-6.
-
(2001)
Nat Genet
, vol.27
, pp. 234-236
-
-
Kruglyak, L.1
Nickerson, D.A.2
-
17
-
-
80052032429
-
'Personalized Medicine' may get a boost
-
Nov. 29, pg. A2.
-
Alonso-Zaldivar R. 'Personalized Medicine' may get a boost. Boston Globe, Nov. 29, 2008 pg. A2.
-
(2008)
Boston Globe
-
-
Alonso-Zaldivar, R.1
-
18
-
-
75549084134
-
Personalized genomic information: preparing for the future of genetic medicine
-
Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010; 11: 161-5.
-
(2010)
Nat Rev Genet
, vol.11
, pp. 161-165
-
-
Guttmacher, A.E.1
McGuire, A.L.2
Ponder, B.3
Stefansson, K.4
-
19
-
-
2342459714
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
-
Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-8.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1382-1388
-
-
Innocenti, F.1
Undevia, S.D.2
Iyer, L.3
-
20
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
-
(2005)
N Engl J Med
, vol.352
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
-
21
-
-
27444443859
-
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
-
Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 15: 801-15.
-
(2005)
Pharmacogenet Genomics
, vol.15
, pp. 801-815
-
-
Salavaggione, O.E.1
Wang, L.2
Wiepert, M.3
Yee, V.C.4
Weinshilboum, R.M.5
-
22
-
-
27744463332
-
Pharmacogenetics/genomics and personalized medicine
-
Spec No. 2: -
-
Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005; 14 Spec No. 2: R207-14.
-
(2005)
Hum Mol Genet
, vol.14
-
-
Sadee, W.1
Dai, Z.2
-
23
-
-
73649109224
-
10years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal
-
Kurnik D, Loebstein R, Halkin H, Gak E, Almog S. 10years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 2009; 10: 1955-65.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1955-1965
-
-
Kurnik, D.1
Loebstein, R.2
Halkin, H.3
Gak, E.4
Almog, S.5
-
24
-
-
33745961962
-
Protein therapeutics: new applications for pharmacogenetics
-
Krejsa C, Rogge M, Sadee W. Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov 2006; 5: 507-21.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 507-521
-
-
Krejsa, C.1
Rogge, M.2
Sadee, W.3
-
25
-
-
0031804517
-
The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4
-
Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-9.
-
(1998)
Nucleic Acids Res
, vol.26
, pp. 216-219
-
-
Kemball-Cook, G.1
Tuddenham, E.G.2
Wacey, A.I.3
-
26
-
-
0042626369
-
The incidence of inhibitor development according to specific mutations--and treatment?
-
Goodeve A. The incidence of inhibitor development according to specific mutations--and treatment? Blood Coagul Fibrinolysis 2003; 14(Suppl. 1): S17-21.
-
(2003)
Blood Coagul Fibrinolysis
, vol.14
, Issue.SUPPL. 1
-
-
Goodeve, A.1
-
27
-
-
0031856491
-
Factor VIII inhibitors in mild and moderate-severity haemophilia A
-
Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
-
(1998)
Haemophilia
, vol.4
, pp. 558-563
-
-
Hay, C.R.1
-
28
-
-
33751014075
-
Genetic risk factors for inhibitors to factors VIII and IX
-
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 6
, pp. 15-22
-
-
Oldenburg, J.1
Pavlova, A.2
-
29
-
-
0033121017
-
Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A
-
Peerlinck K, Jacquemin MG, Arnout J et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
-
(1999)
Blood
, vol.93
, pp. 2267-2273
-
-
Peerlinck, K.1
Jacquemin, M.G.2
Arnout, J.3
-
30
-
-
0034969121
-
The manufacturing process for B-domain deleted recombinant factor VIII
-
Eriksson RK, Fenge C, Lindner-Olsson E et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 24-31.
-
(2001)
Semin Hematol
, vol.38
, pp. 24-31
-
-
Eriksson, R.K.1
Fenge, C.2
Lindner-Olsson, E.3
-
31
-
-
0038383605
-
The epidemiology of inhibitors in haemophilia A: a systematic review
-
Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
-
(2003)
Haemophilia
, vol.9
, pp. 418-435
-
-
Wight, J.1
Paisley, S.2
-
32
-
-
77955492929
-
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
-
Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
-
(2010)
Blood
, vol.116
, pp. 270-279
-
-
Mei, B.1
Pan, C.2
Jiang, H.3
-
33
-
-
53449102958
-
Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
-
Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-9.
-
(2008)
Thromb Res
, vol.122
, Issue.SUPPL. 4
-
-
Schulte, S.1
-
34
-
-
77949884124
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR
-
Suzuki T, Ishii-Watabe A, Tada M et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184: 1968-76.
-
(2010)
J Immunol
, vol.184
, pp. 1968-1976
-
-
Suzuki, T.1
Ishii-Watabe, A.2
Tada, M.3
-
35
-
-
19544378856
-
Haemophilia A: from mutation analysis to new therapies
-
Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 6: 488-501.
-
(2005)
Nat Rev Genet
, vol.6
, pp. 488-501
-
-
Graw, J.1
Brackmann, H.H.2
Oldenburg, J.3
Schneppenheim, R.4
Spannagl, M.5
Schwaab, R.6
-
36
-
-
0027520025
-
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
-
Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236-41.
-
(1993)
Nat Genet
, vol.5
, pp. 236-241
-
-
Lakich, D.1
Kazazian Jr, H.H.2
Antonarakis, S.E.3
Gitschier, J.4
-
37
-
-
0026499294
-
Evidence for a third transcript from the human factor VIII gene
-
Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics 1992; 14: 585-9.
-
(1992)
Genomics
, vol.14
, pp. 585-589
-
-
Levinson, B.1
Kenwrick, S.2
Gamel, P.3
Fisher, K.4
Gitschier, J.5
-
38
-
-
0025118579
-
A transcribed gene in an intron of the human factor VIII gene
-
Levinson B, Kenwrick S, Lakich D, Hammonds G Jr, Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics 1990; 7: 1-11.
-
(1990)
Genomics
, vol.7
, pp. 1-11
-
-
Levinson, B.1
Kenwrick, S.2
Lakich, D.3
Hammonds Jr, G.4
Gitschier, J.5
-
39
-
-
0029095603
-
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study
-
Antonarakis SE, Rossiter JP, Young M et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
-
(1995)
Blood
, vol.86
, pp. 2206-2212
-
-
Antonarakis, S.E.1
Rossiter, J.P.2
Young, M.3
-
40
-
-
0034651552
-
Prevention and treatment of factor VIII inhibitors in murine hemophilia A
-
Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
-
(2000)
Blood
, vol.95
, pp. 1324-1329
-
-
Qian, J.1
Collins, M.2
Sharpe, A.H.3
Hoyer, L.W.4
-
41
-
-
0035139983
-
Danger signals: SOS to the immune system
-
Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114-9.
-
(2001)
Curr Opin Immunol
, vol.13
, pp. 114-119
-
-
Gallucci, S.1
Matzinger, P.2
-
42
-
-
0036951207
-
Genetics of the immune response: identifying immune variation within the MHC and throughout the genome
-
Geraghty DE, Daza R, Williams LM, Vu Q, Ishitani A. Genetics of the immune response: identifying immune variation within the MHC and throughout the genome. Immunol Rev 2002; 190: 69-85.
-
(2002)
Immunol Rev
, vol.190
, pp. 69-85
-
-
Geraghty, D.E.1
Daza, R.2
Williams, L.M.3
Vu, Q.4
Ishitani, A.5
-
43
-
-
58149123374
-
HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population
-
Mack SJ, Tu B, Lazaro A et al. HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 2009; 73: 17-32.
-
(2009)
Tissue Antigens
, vol.73
, pp. 17-32
-
-
Mack, S.J.1
Tu, B.2
Lazaro, A.3
-
44
-
-
33845914334
-
HLA-A, -B, -C, -DRB1 allele and haplotype frequencies in an African American population
-
Tu B, Mack SJ, Lazaro A et al. HLA-A, -B, -C, -DRB1 allele and haplotype frequencies in an African American population. Tissue Antigens 2007; 69: 73-85.
-
(2007)
Tissue Antigens
, vol.69
, pp. 73-85
-
-
Tu, B.1
Mack, S.J.2
Lazaro, A.3
-
45
-
-
70349328358
-
Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses
-
Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-8.
-
(2009)
Blood
, vol.114
, pp. 1423-1428
-
-
Ettinger, R.A.1
James, E.A.2
Kwok, W.W.3
Thompson, A.R.4
Pratt, K.P.5
-
46
-
-
77953176040
-
HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P
-
Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 2010; 16: 44-55.
-
(2010)
Haemophilia
, vol.16
, pp. 44-55
-
-
Ettinger, R.A.1
James, E.A.2
Kwok, W.W.3
Thompson, A.R.4
Pratt, K.P.5
-
47
-
-
36349021392
-
T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide
-
James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2399-2407
-
-
James, E.A.1
Kwok, W.W.2
Ettinger, R.A.3
Thompson, A.R.4
Pratt, K.P.5
|